
**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

FORM 6-K

**REPORT OF FOREIGN ISSUER
PURSUANT TO RULE 13a-16 OR 15d-16
OF THE SECURITIES EXCHANGE ACT OF 1934**

For the month of February, 2025

Commission File No. 001-39621

OPTHEA LIMITED

(Translation of registrant's name into English)

Level 4
650 Chapel Street
South Yarra, Victoria, 3141
Australia
(Address of registrant's principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.
Form 20-F Form 40-F

EXHIBIT INDEX

Exhibit	Description
99.1	<u>Opthea Wet AMD Data Featured at Macula Society Meeting</u>

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereto duly authorized.

OPTHEA LIMITED
(Registrant)

By: /s/ Frederic Guerard
Name: Frederic Guerard
Title: Chief Executive Officer

Date: 02/06/2025



ASX, Nasdaq and Media Release

February 6, 2025

Opthea Wet AMD Data Featured at Macula Society Meeting

Melbourne, Australia, and Princeton, NJ, US, February 6, 2025 -- Opthea Limited (ASX/NASDAQ:OPT, "Opthea", the "Company"), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD), today announced that sozinibcept will be highlighted during an oral presentation at the Macula Society 48th Annual Meeting being held February 12-15, 2025 in Charlotte Harbor, Florida. The Macula Society is a forum for new research in retinal vascular and macular diseases.

Details are as follows:

Session: Neovascular AMD I: Trials

Timing: Friday, February 14, 2025, 8:00 to 8:05 AM ET

Presentation: Sozinibcept Combination Therapy for Neovascular Age-Related Macular Degeneration: Subgroup Analysis of a Phase 2b Study to Assess the Angiographic Predictors of Response

Presenter: David S. Boyer, MD

Program: <https://www.xcdsystem.com/maculasociety/program/5G2onFx/index.cfm?pgid=397&RunRemoveSessionFilter=1>

David S. Boyer, MD will present data from the sozinibcept Phase 2b wet AMD trial demonstrating that superior vision and anatomic outcomes were observed with sozinibcept 2 mg combination therapy, compared with standard-of-care ranibizumab alone, with baseline angiographic lesion characteristics predictive of response.

About Opthea

Opthea (ASX/NASDAQ:OPT) is a biopharmaceutical company developing novel therapies to address the unmet needs in the treatment of highly prevalent and progressive retinal diseases, including wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME).

Opthea's lead product candidate, sozinibcept, is being evaluated in two fully enrolled pivotal Phase 3 clinical trials (COAST, [NCT04757636](https://clinicaltrials.gov/ct2/show/NCT04757636), and SHORe, [NCT04757610](https://clinicaltrials.gov/ct2/show/NCT04757610)) for use in combination with standard-of-care anti-VEGF-A therapies to improve overall efficacy and deliver superior vision gains compared to standard-of-care anti-VEGF-A agents alone.

To learn more, visit our website at www.opthea.com and follow us on [X](#) and [LinkedIn](#).

Authorized for release to ASX by Frederic Guerard, PharmD, CEO

**Investor Inquiries**

PJ Kelleher
LifeSci Advisors LLC
Email: pkelleher@lifesciadvisors.com
Phone: 617-430 7579

Join our email database to receive program updates:

Tel: +61 (0) 3 9826 0399
Email: info@opthea.com
Web: www.opthea.com

Media Inquiries

Silvana Guerci-Lena
NorthStream Global Partners
Email: silvana@nsgpllc.com

Source: Opthea Limited
